Terms: = Kidney tumors AND KLK2, P20151, 3817, ENSG00000167751, MGC12201, hK2, KLK2A2 AND Clinical Outcome
5 results:
1. Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS.
Wang KJ; Meng XY; Chen JF; Wang KY; Zhou C; Yu R; Ma Q
Oxid Med Cell Longev; 2021; 2021():8840590. PubMed ID: 33532038
[TBL] [Abstract] [Full Text] [Related]
2. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
3. Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma.
Yang J; Liu P; Tian M; Li Y; Chen W; Li X
Int J Oncol; 2013 Jun; 42(6):2078-86. PubMed ID: 23588948
[TBL] [Abstract] [Full Text] [Related]
4. Down-regulation of PKCĪ¶ in renal cell carcinoma and its clinicopathological implications.
Pu YS; Huang CY; Chen JY; Kang WY; Lin YC; Shiu YS; Chuang SJ; Yu HJ; Lai MK; Tsai YC; Wu WJ; Hour TC
J Biomed Sci; 2012 Apr; 19(1):39. PubMed ID: 22475628
[TBL] [Abstract] [Full Text] [Related]
5. Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma.
Matsuura K; Nakada C; Mashio M; Narimatsu T; Yoshimoto T; Tanigawa M; Tsukamoto Y; Hijiya N; Takeuchi I; Nomura T; Sato F; Mimata H; Seto M; Moriyama M
BMC Cancer; 2011 Dec; 11():523. PubMed ID: 22185343
[TBL] [Abstract] [Full Text] [Related]
